Spots Global Cancer Trial Database for A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
Official Title: A Phase I Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
Study ID: NCT02381886
Interventions
Study Description
Brief Summary: A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Dana Farber Cancer Institute SC (1), Boston, Massachusetts, United States
Columbia University Medical Center- New York Presbyterian Onc Dept., New York, New York, United States
Uni of TX MD Anderson Cancer Cntr ., Houston, Texas, United States
Novartis Investigative Site, Melbourne, Victoria, Australia
Novartis Investigative Site, Parkville, Victoria, Australia
Novartis Investigative Site, Leuven, , Belgium
Novartis Investigative Site, Toronto, Ontario, Canada
Novartis Investigative Site, Heidelberg, , Germany
Novartis Investigative Site, Jena, , Germany
Novartis Investigative Site, Koeln, , Germany
ErasmusMC Cancer lnstitute, Neuro-Oncology, Rm G3-55, Rotterdam, , Netherlands
Novartis Investigative Site, Singapore, , Singapore
Novartis Investigative Site, Barcelona, Catalunya, Spain
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
